Depomed (NYSE:ASRT) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.
Depomed (NYSE:ASRT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05. The business had revenue of $57.93 million for the quarter, compared to the consensus estimate of $55.51 million.
ASRT opened at $2.85 on Tuesday. The company’s 50 day simple moving average is $3.19. Depomed has a twelve month low of $2.76 and a twelve month high of $9.48.
In other news, Director William Mckee sold 12,500 shares of Depomed stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $4.70, for a total transaction of $58,750.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.
Featured Story: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.